⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806138 | 0.92 | TSHR (0.39) | — | |
| SCHEMBL31299701 | 0.90 | TSHR (0.42) | — | |
| SCHEMBL1167256 | 0.83 | — | — | |
| SCHEMBL11332774 | 0.78 | TSHR (0.41) | — | |
| SCHEMBL27913147 | 0.77 | LPAR2 (0.33) | — | |
| SCHEMBL14351742 | 0.76 | — | — | |
| SCHEMBL13933640 | 0.74 | — | — | |
| SCHEMBL720942 | 0.74 | — | — | |
| SCHEMBL10030567 | 0.74 | ALDH1A1 (0.38) | — | |
| SCHEMBL6300989 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331495-B | Method for preventing inner wall of marine pipe of ship from being corroded and stained | 天津智通新材料科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119331495-A | Method for preventing inner wall of marine pipe of ship from being corroded and stained | 天津智通新材料科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-119331495-B | Method for preventing inner wall of marine pipe of ship from being corroded and stained | 天津智通新材料科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119331495-A | Method for preventing inner wall of marine pipe of ship from being corroded and stained | 天津智通新材料科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024078263-A1 | PREPARATION AND USE OF MACROCYCLIC HETEROCYCLIC COMPOUND AS EGFR INHIBITOR | 药雅科技(上海)有限公司 | 2024-04-18 | — | — | WO | disclosed |
| CN-117229300-A | Preparation and application of EGFR inhibitor | 药雅科技(上海)有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11760736-B2 | Processes and intermediates for preparing MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-7879797-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| EP-1879607-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007068822-A2 | SULPHONYL-1,2,4-TRIAZOLE SALTS | PHOSTECH LITHIUM INC. (CA) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006119061-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119061-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |